Dr. Praveen Chandra
Chairman
39 years of experienceInterventional Cardiologists
MBBS, MD, DM, FIC, FACC, FAPSIC, FSCAI, FESC, FEISI
Medanta - The Medicity Medical Centre, Gurgaon
Book an AppointmentAbout Dr. Praveen Chandra
Dr. Praveen Chandra stands as a distinguished figure in the field of Interventional Cardiology within India, well?recognized for his profound expertise and pioneering advancements in interventional cardiology. With an extensive career spanning 39, Dr. Chandra conducts over 5000 percutaneous and diagnostic interventions annually, showcasing his vast professional experience and skill. He focuses on innovative techniques aimed at minimizing the necessity for open-heart surgeries. He notably executed the first Percutaneous Aortic Valve implantation without surgery in India. Dr. Chandra is credited with the development of methodologies aimed at reducing the requirement for bypass surgeries, alongside enhancing the accuracy of angioplasty procedures for treating multiple blocked arteries. His groundbreaking utilization of the Fractional Flow Reserve (FFR) technique on a 78-year-old patient garnered widespread recognition, earning him a feature in The Times of India. Frequently sought after as a keynote speaker and faculty member at conferences, Dr. Chandra actively shares his insights and presents his research findings, organizing seminars and meetings to foster advancements in interventional cardiology. His educational journey started with MBBS from King George's Medical Coll., Lucknow Univ., 1985, followed by MD (Medical Genetics) from King George's Medical Coll., Lucknow Univ., 1989, and DM (Cardiology) from King George's Medical Coll., Lucknow Univ., 1991. Dr. Chandra also achieved various fellowships including that of Interventional Cardiology Univ. of Rouen, France, 1995, American Coll. of Cardiology, 2006, Asia-Pacific Society of Interventional Cardiology, 2006, Society of Cardiovascular Angiography and Intervention, 2006, European Society of Cardiology, 2007, and Endovascular Intervention Society of India. Acknowledged for his monumental contributions, particularly in the realm of coronary angioplasty, Dr. Chandra has received numerous accolades. A pivotal part of the pioneering team in Asia that initiated the Percutaneous Myocardial Laser Revascularization Program, his impact on the field is undeniable. Dr. Chandra boasts a prolific publication record, with over 100 publications comprising abstracts, articles, and publications in esteemed national and international medical journals. He is an active part of the Cardiological Society of India (CSI) and the American Coll. of Cardiology.Education
MBBS, King George's Medical Coll., Lucknow Univ., 1985 MD (Medical Genetics), King George's Medical Coll., Lucknow Univ., 1989 DM (Cardiology) King George's Medical Coll., Lucknow Univ., 1991 Fellow Interventional Cardiology Univ. of Rouen, France (FIC), 1995 a fellow of the American Coll. of Cardiology (FACC), 2006 a fellow of the Asia-Pacific Society of Interventional Cardiology (FAPSIC), 2006 a fellow of the Society of Cardiovascular Angiography and Intervention (FSCAI), 2006 a fellow of the European Society of Cardiology (FESC), 2007 a fellow of the Endovascular Intervention Society of India (FEIS)Past Experience
Director, Max Heart & Vascular Inst., Saket, New Delhi, India, 2010 Senior Consultant, Escorts Heart Inst. and Research Center, New Delhi, India, 2004 Senior Resident, King George Medical Coll., 1992 Senior Resident, King George Medical Coll., 1989 House Officer, King George Medical Coll., 1987 Internship Trainee, King George Medical Coll., 1986Awards
Recognition accolade for Success and achievement in the field of angioplasty in India - 1998 Padma Shri accolade - 2016
Associations/Membership
Cardiological Society of India (CSI) American Coll. of Cardiology
Paper Published
Dr. Praveen Chandra brings more than 100 publications to his name, some of which are mentioned below: Safety and effectiveness of the novel Myval Octacor transcatheter heart valve in severe, symptomatic aortic valve stenosis — A real-world Indian professional experience (The OCTACOR India Study). Angiographic quantification of aortic regurgitation following myval octacor implantation; independent core lab adjudication. Clinical expert consensus document on the use of percutaneous left ventricular assist devices during complex, high-risk PCI in India using a standardized algorithm. Clinical evaluation of the Hydra self?expanding transcatheter aortic valve: 6-month results from the GENESIS trial. Evaluation of Balloon Expandable Transcatheter Heart Valve in the Treatment of Severe Symptomatic Native Aortic Stenosis: The First-in-human MyVal-1 Study. First-in-Human Evaluation of Balloon Expandable Transcatheter Heart Valve in the Treatment of Severe Symptomatic Native Aortic Stenosis: The MyVal-1 Study. Three-year clinical and two-year multimodality imaging outcomes of a thin-strut sirolimus-eluting bioresorbable vascular scaffold: MeRes-1 trial. Pharmacokinetic Study of Sirolimus-Eluting BioResorbable Vascular Scaffold System for Treatment of De Novo Native Coronary Lesions: A Sub-Study of MeRes-1 Trial. TCT-64 Two-Year Clinical and Imaging Outcomes of Thin Strut Sirolimus-Eluting Bioresorbable Vascular Scaffolds in De Novo Coronary Artery Lesions: The MeRes-1 Trial. First-in-human evaluation of a novel poly-L-lactide based sirolimus-eluting bioresorbable vascular scaffold for the treatment of de novo native coronary artery lesions: MeRes-1 trial. TCTAP A-003 First-in-human Evaluation of a Novel Poly-L-lactide Based Sirolimus-eluting Bioresorbable Vascular Scaffold for the Treatment of De Novo Native Coronary Artery Lesions: MeRes-1 Trial TCTAP A-058 Favorable Outcomes for Systemic Pharmacokinetic Study of Sirolimus-eluting Bioresorbable Vascular Scaffold System in Treating De Novo Native Coronary Artery Lesion: A Sub Study of MeRes-1 Trial. CRT-700.01 Favourable Outcomes for Systemic Pharmacokinetic Study of Sirolimus-Eluting BioResorbable Vascular Scaffold System in Treating de novo Native Coronary Artery Lesion: A Sub Study of MeRes-1 Trial. Clinical Characteristics and Outcomes after Unplanned Intra aortic Balloon Counterpulsation in the Counterpulsation to Reduce Infarct Size Pre-PCI Acute Myocardial Infarction Trial. A prospective, multicenter, post-marketing surveillance study to evaluate the safety and effectiveness of the Superia-Sirolimus Eluting Coronary Stent System (SSECSS) implanted during routine clinical practice in India.
Area of Expertise
- 24-Hour Holter Monitoring
- 64-Slice CT Angiography
- Ablation Therapy
- Ambulatory BP Monitoring (ABPM)
- Aneurysm Surgery: Traditional Open Surgery
- Angiography